Bioscience

Primus wins new patent for osteoarthritis prescription medical food product

May 27, 2009

By Flinn Foundation

[Source: Datamonitor via COMTEX] – Primus Pharmaceuticals, a specialty pharmaceutical company engaged in the development of prescription metabolic products, has received a new composition of matter patent for Limbrel, the first prescription medical food product to safely meet the distinctive nutritional requirements of patients with osteoarthritis, from the US Patent and Trademark Office.

Limbrel contains flavocoxid, a proprietary composition of natural flavonoid ingredients from the plant sources of Scutellaria baicalensis and Acacia catechu that meet FDA strict safety standard of generally recognized as safe (GRAS).

For more information click here.